These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27956428)

  • 1. Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
    Griffin MP; Khan AA; Esser MT; Jensen K; Takas T; Kankam MK; Villafana T; Dubovsky F
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.
    Domachowske JB; Khan AA; Esser MT; Jensen K; Takas T; Villafana T; Dubovsky F; Griffin MP
    Pediatr Infect Dis J; 2018 Sep; 37(9):886-892. PubMed ID: 29373476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
    Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
    Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
    Aliprantis AO; Wolford D; Caro L; Maas BM; Ma H; Montgomery DL; Sterling LM; Hunt A; Cox KS; Vora KA; Roadcap BA; Railkar RA; Lee AW; Stoch SA; Lai E
    Clin Pharmacol Drug Dev; 2021 May; 10(5):556-566. PubMed ID: 33125189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
    Brady T; Cayatte C; Roe TL; Speer SD; Ji H; Machiesky L; Zhang T; Wilkins D; Tuffy KM; Kelly EJ
    Front Immunol; 2023; 14():1283120. PubMed ID: 37901217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P; Trenholme A; Abarca K; Griffin MP; Hultquist M; Harris B; Losonsky GA;
    BMC Pediatr; 2010 Jun; 10():38. PubMed ID: 20525274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.
    Meissner HC; Groothuis JR; Rodriguez WJ; Welliver RC; Hogg G; Gray PH; Loh R; Simoes EA; Sly P; Miller AK; Nichols AI; Jorkasky DK; Everitt DE; Thompson KA
    Antimicrob Agents Chemother; 1999 May; 43(5):1183-8. PubMed ID: 10223933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897.
    Zhu Q; Lu B; McTamney P; Palaszynski S; Diallo S; Ren K; Ulbrandt ND; Kallewaard N; Wang W; Fernandes F; Wong S; Svabek C; Moldt B; Esser MT; Jing H; Suzich JA
    J Infect Dis; 2018 Jul; 218(4):572-580. PubMed ID: 29617879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
    N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
    Bergeron HC; Tripp RA
    Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults.
    Orito Y; Otani N; Matsumoto Y; Fujimoto K; Oshima N; Maas BM; Caro L; Aliprantis AO; Cox KS; Tokumaru O; Kodama M; Kudo H; Imai H; Uemura N
    Clin Transl Sci; 2022 Jul; 15(7):1753-1763. PubMed ID: 35506164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
    Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
    Claydon J; Sur A; Callejas A; Ladd M; Kwan E; Taylor R; Turvey SE; Solimano A; Lavoie PM; Marr N
    PLoS One; 2017; 12(4):e0176152. PubMed ID: 28437470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.
    Mejias A; Garcia-Maurino C; Rodriguez-Fernandez R; Peeples ME; Ramilo O
    Vaccine; 2017 Jan; 35(3):496-502. PubMed ID: 27692523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
    Aliprantis AO; Shaw CA; Griffin P; Farinola N; Railkar RA; Cao X; Liu W; Sachs JR; Swenson CJ; Lee H; Cox KS; Spellman DS; Winstead CJ; Smolenov I; Lai E; Zaks T; Espeseth AS; Panther L
    Hum Vaccin Immunother; 2021 May; 17(5):1248-1261. PubMed ID: 33121346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.
    Ferrero F; Lin CY; Liese J; Luz K; Stoeva T; Nemeth A; Gijón M; Calvo C; Natalini S; Toh TH; Deleu S; Chen B; Rusch S; Sánchez BL; Leipoldt I; Vijgen L; Huntjens D; Baguet T; Bertzos K; Gamil M; Stevens M;
    Paediatr Drugs; 2024 Jul; 26(4):411-427. PubMed ID: 38649595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants.
    Jorgensen SCJ
    J Antimicrob Chemother; 2023 May; 78(5):1143-1149. PubMed ID: 36922390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.